Literature DB >> 2114394

Combination treatment with irritant and recombinant interleukin 2 in the peritoneal cavity for evoking effective anti-tumor activity: generation of lymphokine-activated killer cells and tumor-specific killer cells.

H Uchida1, K Taniguchi, K Nomoto.   

Abstract

Meth A sarcoma, growing in the subcutaneous tissue of syngeneic BALB/c mice, regressed completely after an intraperitoneal (ip) injection of proteose peptone (PP) (on day 6) followed by 2 ip administrations (on days 7 and 8) of human recombinant interleukin-2 (IL-2, 25 micrograms/day), whereas one such treatment alone had little effect on the tumor growth. While this combination treatment was effective in anti-asialo GM1 antibody-treated mice, no such effect was noted in T cell-depleted ATXFL (thymectomized, irradiated and fetal liver cell-reconstituted) mice. These results show that T cells are mainly responsible for this antitumor effect. Treatment with a combination of PP and IL-2, but not with either PP or IL-2 alone, resulted in a marked increase in the T cell population in the peritoneal cavity after the treatment. At an early stage after the combination treatment, both peritoneal exudate cells (PEC) and spleen cells exhibited killing activity with a promiscuous specificity. However, at a later stage, 7 days after the treatment, Meth A-specific killer activity was observed in both PEC and the spleen. Meth A rechallenge was rejected by the mice in which the tumor had regressed, but the antigenically different Meth 1 was accepted by them. A similar result was obtained in Winn's neutralization test. These results suggest that this combination treatment, which is effective in the generation of lymphokine-activated killer cells in the peritoneal cavity, finally resulted in the induction of tumor-specific killer cells in the periphery. These results clearly show the anti-tumor efficacy of combination treatment with PP and rIL-2.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2114394      PMCID: PMC5918044          DOI: 10.1111/j.1349-7006.1990.tb02584.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


interleukin‐2 proteose‐peptone natural killer lymphokine‐activated killer peritoneal exudate cells adult thymectomized, irradiated and reconstituted with fetal liver cells
  22 in total

1.  Immune mechanisms in homotransplantation. II. Quantitative assay of the immunologic activity of lymphoid cells stimulated by tumor homografts.

Authors:  H J WINN
Journal:  J Immunol       Date:  1961-02       Impact factor: 5.422

2.  Inverse relationship in H-2-associated lysis between NK cells and rIL-2-activated killer cells: evidence from in vitro killing and metastatic experiments.

Authors:  A Toshitani; K Taniguchi; Y Kawano; K Nomoto
Journal:  Cell Immunol       Date:  1987-08       Impact factor: 4.868

3.  Purification and characterization of recombinant human interleukin-2 produced in Escherichia coli.

Authors:  K Kato; T Yamada; K Kawahara; H Onda; T Asano; H Sugino; A Kakinuma
Journal:  Biochem Biophys Res Commun       Date:  1985-07-31       Impact factor: 3.575

4.  Blocking of cell-mediated tumor immunity by sera from patients with growing neoplasms.

Authors:  I Hellström; H O Sjögren; G Warner; K E Hellström
Journal:  Int J Cancer       Date:  1971-03-15       Impact factor: 7.396

5.  In vivo effects of anti-asialo GM1. I. Reduction of NK activity and enhancement of transplanted tumor growth in nude mice.

Authors:  S Habu; H Fukui; K Shimamura; M Kasai; Y Nagai; K Okumura; N Tamaoki
Journal:  J Immunol       Date:  1981-07       Impact factor: 5.422

6.  Cytotoxic T-cell-mediated antitumor effect of levamisole against murine syngeneic fibrosarcoma.

Authors:  K Gomi; M Morimoto; K Nomoto
Journal:  Cancer Res       Date:  1982-10       Impact factor: 12.701

7.  Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2.

Authors:  J J Mulé; S Shu; S L Schwarz; S A Rosenberg
Journal:  Science       Date:  1984-09-28       Impact factor: 47.728

8.  Intrapleural administration of OK432 in cancer patients: activation of NK cells and reduction of suppressor cells.

Authors:  A Uchida; M Micksche
Journal:  Int J Cancer       Date:  1983-01-15       Impact factor: 7.396

9.  Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.

Authors:  E A Grimm; A Mazumder; H Z Zhang; S A Rosenberg
Journal:  J Exp Med       Date:  1982-06-01       Impact factor: 14.307

10.  Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

Authors:  S A Rosenberg; J J Mulé; P J Spiess; C M Reichert; S L Schwarz
Journal:  J Exp Med       Date:  1985-05-01       Impact factor: 14.307

View more
  1 in total

1.  Generation of tumor-specific cytotoxic T lymphocytes in vivo by combined treatment with inactivated tumor cells and recombinant interleukin-2.

Authors:  M Harada; G Matsuzaki; Y Shinomiya; S Kurosawa; O Ito; T Okamoto; M Takenoyama; H Sumitika; Y Nishimura; K Nomoto
Journal:  Cancer Immunol Immunother       Date:  1994-05       Impact factor: 6.968

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.